CPK13

CPK13 is an experimental **small-molecule** blocker of the **KCNT1 potassium channel** being investigated preclinically as a potential therapy for **KCNT1-related epilepsies**. It was identified through **in silico screening** and subsequently characterized in vitro as a **potent, selective KCNT1 inhibitor** with greater blocking potency than quinidine in reported assays and selectivity over hERG and Kv7.2 channels. Electrophysiology data indicate relatively **slow blocking kinetics** and **limited reversibility on washout**, and molecular modeling suggests interactions with KCNT1 channel residues including **S313** and **F346**. No clinical development, brand name, or commercial manufacturer has been established from the provided evidence.